Privately held Atlanta, GA-based Arbor Pharmaceuticals, LLC acquires XenoPort (NASDAQ:XNPT) for $7.03 in cash or ~$467M. The deal should close in Q3.
Arbor markets prescription drugs for the cardiovascular, hospital, neuroscience and pediatric markets. XenoPort markets Horizant (gabapentin enacarbil) for restless leg syndrome. The product is branded as Regnite in Japan. Pipeline products include XP23829 for psoriasis and multiple sclerosis and XP21279 for Parkinson’s disease.
